OmniAb logo

OmniAb(NASDAQ) OABIW

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-48%
5 Year-49%
1 Year+69%
1 Month-23%
$0.28
-26.84%
-0.10Today
OmniAb last closing stock price
MetricPriceDate
Last closeUSD 0.282026-10-13
OmniAb stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-27.31%USD 0.392026-10-06
1 month-22.86%USD 0.372026-09-11
3 month+250.43%USD 0.082026-07-15
Year to date+136.45%USD 0.122025-12-31
1 year+68.75%USD 0.172025-10-10
3 year-69.53%USD 0.932023-10-13
5 year-49.38%USD 0.562021-10-14
Since inception-48.45%USD 0.552021-09-30

OmniAb Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$38.43M

Net Income (TTM)

-$44.26M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.48 (Low)

Price

$0.28

Volume

307

Open

$0.24

Previous Close

$0.28

Daily Range

$0.22 - $0.28

52-Week Range

$0.04 - $0.42

Estimated Earnings Date

Nov 17, 2026

OABIW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About OmniAb

OmniAb, Inc. is a biotechnology firm based in Emeryville, California, specializing in innovative technologies for therapeutic antibody discovery. Established in 2012, the company offers a unique OmniAb platform that enables partners to develop next-generation therapeutic agents through proprietary transgenic animals.

Products and Services
  • OmniAb platform for antibody discovery
  • Proprietary transgenic animals: OmniRat, OmniChicken, OmniMouse
  • Specialized models: OmniFlic and OmniClic for bispecific antibodies
Growth Outlook
  • Recent quarterly revenue of $13.4 million indicates strong market demand
  • TTM gross profit margin of 50.5% reflects operational efficiency
  • Cash and short-term investments of $51.9 million support future growth initiatives
Financial Highlights
  • Q2 2026 net income loss narrowed to $5.9 million from $7.7 million in Q1
  • Operating expenses decreased to $19.4 million in Q2 2026
  • Current ratio of 4.8 suggests strong liquidity position
OmniAb, Inc. is positioned in the biotechnology sector, focusing on the development of therapeutic antibodies. The company's flagship OmniAb platform leverages proprietary transgenic animals to streamline the discovery process, making it a valuable partner for industry collaborators. Recent financial performance shows a positive trend, with a notable increase in quarterly revenue and a significant gross profit margin. The company's liquidity is robust, as indicated by a current ratio of 4.8, allowing for flexibility in pursuing growth opportunities. As the demand for innovative therapeutic solutions continues to rise, OmniAb's unique offerings and strong financial position may attract interest from potential investors.
AI Generated • Oct 11, 2026

Industry

Life Sciences Tools and Services

Headquarters

EmeryVille, CA 94608, US

OABIW Financials

Key Financial Metrics (TTM)

Gross Margin

50.53%

Operating Margin

-125.79%

Net Income Margin

-115.18%

Return on Equity

-16.59%

Return on Capital

-24.89%

Return on Assets

-15.25%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

307

Avg. Volume

11.79K

Financials (TTM)

Gross Profit

$19.42M

Operating Income

-$48.34M

EBITDA

-$20.03M

Operating Cash Flow

-$17.67M

Capital Expenditure

-$468.00K

Free Cash Flow

-$18.14M

Cash & ST Invst.

$52.00M

Total Debt

$18.91M

OmniAb Performance Analysis

OmniAb sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-42.5%
Q42025-12-31274.1%
Q12026-03-3171.9%
Q22026-06-30-6.8%
OmniAb sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-306.7%
Q42025-12-3121.4%
Q12026-03-3145.5%
Q22026-06-3016.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$13.42M

+244.2%

Gross Profit

$12.81M

+252.3%

Gross Margin

95.45%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

89

N/A

Net Income

-$5.86M

+63.1%

EBITDA

-$1.99M

+86.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$52.00M

+24.9%

Total Debt

$18.91M

-13.2%

Accounts Receivable

$10.33M

+281.7%

Inventory

$0.00

N/A

Long Term Debt

$14.94M

-16.7%

Short Term Debt

$3.97M

+3.4%

Return on Assets

-15.25%

N/A

Return on Invested Capital

-17.48%

N/A

Free Cash Flow

$2.57M

+148.4%

Operating Cash Flow

$2.68M

+152.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MGNXMacroGenics, Inc.
$3.42-8.06%
STROSutro Biopharma, Inc.
$11.01-17.09%
VRXAVeraxa Biotech Holding AG
$1.20+5.26%
ABSIAbsci Corporation
$9.10-5.89%

Trending Stocks

Symbol / CompanyPricePrice Chg
CIFRCipher Digital
$11.34-12.77%
BMBLBumble
$5.95+56.58%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$37.42+0.62%
INTCIntel
$102.81+1.44%

Questions About OABIW

What is the current price of OmniAb?

OmniAb is trading at $0.28 per share.

What is the 52-week range for OmniAb?

Over the past 52 weeks, OmniAb has traded between $0.04 and $0.42.

How much debt does OmniAb have?

OmniAb total debt is unavailable.

How much cash does OmniAb have on hand?

OmniAb does not have cash on hand data available.

What is OmniAb’s dividend yield?

OmniAb does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.